.png){kind=icon}
.png){kind=icon}
Return
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group
.png){kind=icon}
OA
AI
DOI：10.1182/bloodadvances.2025017234.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Outcomes of patients with RR mantle cell lymphoma failing CAR-T cell therapy is particularly poor, without standardized salvage option. • Bispecific antibodies appear to be a promising therapeutic option, offering durable responses compared to chemotherapy and targeted therapy.
Keywords:
Mantle cell lymphoma
brexu-cel
failure
outcomes
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.1
Papers:
6.0K
Citations:
2.3W
Organization
H
A
View more organizations